Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3143563rdf:typepubmed:Citationlld:pubmed
pubmed-article:3143563lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C1096063lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C0055891lld:lifeskim
pubmed-article:3143563lifeskim:mentionsumls-concept:C2003855lld:lifeskim
pubmed-article:3143563pubmed:issue4lld:pubmed
pubmed-article:3143563pubmed:dateCreated1989-1-17lld:pubmed
pubmed-article:3143563pubmed:abstractTextTwenty-five out of 41 (61%) patients with drug-resistant complex partial seizures showed an initial dramatic response to clobazam. Sixteen of these responders developed tolerance to the effects of clobazam so that only 9 (22%) maintained a dramatic response for 1 year. Factors which appeared important in predicting a dramatic response to treatment were a known aetiology for the epilepsy, the occurrence of complex partial seizures alone (i.e., without secondary generalisation) and the absence of mental retardation.lld:pubmed
pubmed-article:3143563pubmed:languageenglld:pubmed
pubmed-article:3143563pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3143563pubmed:citationSubsetIMlld:pubmed
pubmed-article:3143563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3143563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3143563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3143563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3143563pubmed:statusMEDLINElld:pubmed
pubmed-article:3143563pubmed:issn0920-1211lld:pubmed
pubmed-article:3143563pubmed:authorpubmed-author:ReynoldsE HEHlld:pubmed
pubmed-article:3143563pubmed:authorpubmed-author:RingH AHAlld:pubmed
pubmed-article:3143563pubmed:authorpubmed-author:HellerA JAJlld:pubmed
pubmed-article:3143563pubmed:issnTypePrintlld:pubmed
pubmed-article:3143563pubmed:volume2lld:pubmed
pubmed-article:3143563pubmed:ownerNLMlld:pubmed
pubmed-article:3143563pubmed:authorsCompleteYlld:pubmed
pubmed-article:3143563pubmed:pagination276-80lld:pubmed
pubmed-article:3143563pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:meshHeadingpubmed-meshheading:3143563-...lld:pubmed
pubmed-article:3143563pubmed:articleTitleFactors relating to dramatic response to clobazam therapy in refractory epilepsy.lld:pubmed
pubmed-article:3143563pubmed:affiliationUniversity Department of Neurology, King's College Hospital, London, U.K.lld:pubmed
pubmed-article:3143563pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3143563lld:pubmed